Adverse Effects of CDK4/6 Inhibitor Palbociclib

  • Neutropenia:
    • Is found in up to 79.5% of patients on Palbociclib:
      • Neutropenia and the risk for infections:
        • Must be discussed with patients prior to initiation of treatment
  • Other common adverse effects of this drug include:
    • Fatigue (37.4%)
    • Nausea (35.1%)
    • Alopecia (32.9%)
  • References
    • Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast cancer. New Engl J Med. 2016;375(20):1925-1936.
    • Finn RS, Crown JP2, Lang I3, Boer K4, Bondarenko IM5, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.

Leave a comment